Get the Weekly Intelligence Brief — top committee picks every Sunday.

IOVA vs PTGX

Iovance Biotherapeutics, Inc. vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
IOVA
Iovance Biotherapeutics, Inc.
64
Buy
VS
PTGX
Protagonist Therapeutics, Inc.
64
Buy
MetricIOVAPTGX
AI Score 64 64
Price $6.74 $151.99
P/E Ratio -9.27× 121.74×
ROE -56.0% -21.2%
Revenue Growth YoY
Gross Margin 116.3% 99.9%
Debt / Equity 0.06× 0.01×
Dividend Yield 0.0% 0.0%
RSI (14) 79.2 68.1
Beta 0.701 1.794
Expected Upside

AI Committee View

Current Innellis committee reasoning for IOVA versus PTGX.
The committee scores are tied.

IOVA and PTGX both score 64/100.

IOVA Committee View
67% agreement
6 analysts

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull Case
  • Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
Bear Case
  • ROE of only -40.5% -- cheap may mean cheap for a reason — Value
  • RSI at 79 is in overbought territory — Technical
  • Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
PTGX Committee View
67% agreement
6 analysts

The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
  • EPS growing 46.0% YoY — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
  • P/E of 115.4 is expensive by classic value standards — Value
  • Price-to-book of 8.9x prices in significant intangible value — Value
  • Weekly RSI at 84 -- overbought on the larger timeframe too — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
IOVA Full Analysis PTGX Full Analysis